94 results about "Gut barrier" patented technology

The present invention relates to nutritional compositions comprising 6'- sialyllactose (6'SL) and lacto-N-tetraose (LNT) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gut barrier function in an infant, a young child or children aged above 3 years to 8 years.

A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and / or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and / or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and / or obesity; an enteropathogenic infection; impaired gut barrier function and / or; an inflammation related to gastro intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

The invention discloses bifidobacterium longum for relieving ulcerative colitis and application of the bifidobacterium longum, and belongs to the technical field of microorganisms. The Bifidobacterium longum NSP001 disclosed by the invention can stimulate human colon cancer cells Caco-2 to secrete superoxide dismutase, and can improve weight loss and DAI indexes of mice with ulcerative colitis, relieve damage to intestinal barriers and tissue structures, regulate secretion of inflammatory factors and oxidative stress level under the conditions of mouse and human intestinal florae, and can be used for preparing the superoxide dismutase for treating the ulcerative colitis and preventing and treating the ulcerative colitis, so that the bifidobacterium longum NSP001 can be used for preparing the superoxide dismutase for treating the ulcerative colitis. The production of intestinal short-chain fatty acid is promoted, the flora function is improved, and the intestinal health is recovered. In addition, the bifidobacterium longum can further prevent or relieve body metabolic disorder accompanied by enteritis. The bifidobacterium longum NSP001 is used for preparing a pharmaceutical composition and fermented food for relieving ulcerative colitis, and has a very wide application prospect.

The invention relates to the technical field of medicines, in particular to an application of a bromodomain protein 4 (BRD4) inhibitor JQ1 or a derivative thereof in preparation of a medicine for treating sepsis intestinal barrier injury. Experiments show that in a lipopolysaccharide (LPS)-induced sepsis mouse intestinal barrier injury model, the BRD4 inhibitor JQ1 can effectively inhibit LPS-induced sepsis mouse intestinal mucosa damage, release of inflammatory factors TNF[alpha], IL1[beta] and IL18, release of NLRP3 complex inflammasome, and high expression of pyroptosis marker genes GSDMD,GSDME, P2X7 and Aim2. Results show that the BRD4 inhibitor JQ1 can effectively prevent the sepsis mouse intestinal barrier injury by inhibiting intestinal tissue cell pyroptosis, and can be used for preparing a pharmaceutical preparation for treating the sepsis intestinal barrier injury.

The present invention relates to administration of sweet whey protein (SWP) for promoting the enteric neuronal development in infants, especially preterm, low birth, very low and extremely low birth weight infants as well as in young children up until the age of six. Administration of the SWP according to the invention prevents and treats disorders associated with an immature or impaired enteric nervous system. The disorders are, notably, dysfunctional gastrointestinal motility manifested as slow intestinal transit, intestinal discomfort, hard stools, constipation and / or gastrointestinal reflux, gut barrier dysfunction, food intolerance or necrotizing enterocolitis.

The invention discloses a plant extract additive for improving intestinal health of livestock and poultry, and belongs to the field of feed additives. Intestinal tracts are digestion and absorption places of livestock and poultry nutrient substances, intestinal tract damage certainly causes diarrhea, diarrhea and the like, the phenomena of low feed conversion rate, reduced growth performance and the like are caused. The plant extract additive comprises the following main components: 10-30 parts of a plant essential oil compound, 10-30 parts of plant polysaccharide, 10-20 parts of medium and short chain fatty acid and 50-70 parts of a carrier, wherein the plant essential oil compound is prepared by mixing one or more of cinnamyl aldehyde, thymol, carvacrol, eugenol and allicin according to a specific proportion; the plant polysaccharide is prepared by mixing one or more of astragalus polysaccharide, ganoderma lucidum polysaccharide and gingko polysaccharide according to a specific proportion; and the medium and short chain fatty acid is prepared by mixing one or more of caprylic acid, capric acid and lauric acid according to a specific proportion. Breeding test results show that the plant extract compound feed additive has the functions of obviously improving intestinal flora structures of the livestock and poultry, promoting intestinal villus development and the like besides remarkable anti-inflammation and sterilization effects. The feed additive has the characteristics of wide antibacterial spectrum, difficulty in generating drug resistance, no pollution to the environment and the like, can effectively kill harmful bacteria in intestinal tracts of livestock and poultry, also has the effects of promoting intestinal villus development, intestinal barrier repair and the like, improves the digestion and absorption of organisms on nutrient substances, enhances the disease resistance of flora and improves the breeding benefits of the livestock and poultry.

The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing secretion of >200 pg / ml of IL-10, and / or iii) inducing an IL-10:IL-12 ratio >1 when co-incubated with human PBMC derived dendritic cells. The strains may have one, two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention, alleviation of symptoms, and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro-inflammatory activation of the mucosa. More specifically, the present invention relates to se of an isolated strain according to the invention for the prevention, alleviation of symptoms, or treatment of intestinal inflammatory conditions such as IBD and IBS, liver diseases such as NAFLD, NASH, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, type 2 diabetes, obesity, cardiovascular atherosclerosis, autoimmune diseases, such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.

The invention relates to an improvement of completeness of an intestinal barrier, in particular to a method for exciting the barrier completeness of mammalian by applying a composition containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA) and at least two different oligosaccharides to the mammalians.

The present invention relates, inter alia, to ghrelin analogs and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and / or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.

The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

The invention discloses application of rutin as a growth promoting agent in poultry feed. It is found for the first time that when 200-1500 mg / kg of rutin is added into a feed for white feather broilers, the immunity of the broilers can be effectively enhanced, the intestinal barrier function is improved, ingestion of the broilers is promoted, and the daily gain and the feed utilization efficiency are improved. The rutin disclosed by the invention has the advantages of being green, environment-friendly, wide in source, low in cost and the like, and is a safe and efficient green feed growth promoting additive.

This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.